Phenotypes associated with this allele

• Allele Symbol: Col1a1^{tm1(tetO-YAP1*)Fcam}
• Allele Name: targeted mutation 1, Fernando D Camargo
• Allele ID: MGI:5316453
• Summary: 4 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Col1a1^tm1(tetO-YAP1*)Fcam/Col1a1^+ Gt(ROSA)26Sor^tm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor^+ Tg(KRT14-cre)1Amc/0	involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * CBA	MGI:5316468
cn2	Col1a1^tm1(tetO-YAP1*)Fcam/Col1a1^+ Gt(ROSA)26Sor^tm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor^+ Tg(Pbsn-cre)4Prb/0	involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * DBA/2	MGI:5705651
cx3	Col1a1^tm1(tetO-YAP1*)Fcam/Col1a1^+ Tg(Cebpb-tTA)#Bjd/0	involves: 129S4/SvJae * C57BL/6	MGI:5316652
cx4	Col1a1^tm1(tetO-YAP1*)Fcam/Col1a1^+ Gt(ROSA)26Sor^tm1(rtTA*M2)Jae/Gt(ROSA)26Sor^+	involves: 129S4/SvJae * C57BL/6	MGI:5316663

Genotype
MGI:5316468

cn1

• Allelic Composition: Col1a1^{tm1(tetO-YAP1*)Fcam}/Col1a1⁺; Gt(ROSA)26Sor^{tm1(rtTA,EGFP)Nagy}/Gt(ROSA)26Sor⁺; Tg(KRT14-cre)1Amc/0
• Genetic Background: involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * CBA

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

integument

abnormal hair growth ( J:171057 )

• skin grafts on nude mice treated with doxycycline exhibit stunted hair growth unlike control grafts

abnormal epidermal layer morphology ( J:171057 )

• doxycycline-treated mice exhibit multi-layered epithelium unlike control mice

hyperkeratosis ( J:171057 )

• skin grafts on nude mice treated with doxycycline exhibit hyperkeratosis unlike control grafts

thick epidermis ( J:171057 )

• skin grafts on nude mice treated with doxycycline exhibit hyperkeratosis unlike control grafts

wrinkled skin ( J:171057 )

• 8 days after doxycycline treatment

thick skin ( J:171057 )

• 8 days after doxycycline treatment

abnormal epidermal stem cell morphology ( J:171057 )

• skin from doxycycline-treated mice exhibit a greater than 5-fold increase in the number of colony-forming cells compared with skin from control mice

increased skin squamous cell carcinoma incidence ( J:171057 )

• in nude mice receiving skin grafts and treated with doxycycline

craniofacial

abnormal tongue epithelium morphology ( J:171057 )

• thickened and dysplastic in doxycycline-treated mice

neoplasm

increased skin squamous cell carcinoma incidence ( J:171057 )

• in nude mice receiving skin grafts and treated with doxycycline

cellular

increased cell proliferation ( J:171057 )

• doxycycline-treated mice exhibit increased cell proliferation of basal cells and an extension of the proliferative domain into the suprabasal layers of back skin compared with control mice

digestive/alimentary system

abnormal tongue epithelium morphology ( J:171057 )

• thickened and dysplastic in doxycycline-treated mice

growth/size/body

abnormal tongue epithelium morphology ( J:171057 )

• thickened and dysplastic in doxycycline-treated mice

Genotype
MGI:5705651

cn2

• Allelic Composition: Col1a1^{tm1(tetO-YAP1*)Fcam}/Col1a1⁺; Gt(ROSA)26Sor^{tm1(rtTA,EGFP)Nagy}/Gt(ROSA)26Sor⁺; Tg(Pbsn-cre)4Prb/0
• Genetic Background: involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * DBA/2

neoplasm

increased prostate gland tumor incidence ( J:222916 )

♂ • 4 of 11 mice administered doxycycline at 3 months of age develop prostate tumors with age

♂ • tumors include adenocarcinomas, sarcomatoid carcinomas (epithelial-mesenchymal transition-like epithelial tumor), and stromal-type tumors

increased prostate gland adenocarcinoma incidence ( J:222916 )

♂

endocrine/exocrine glands

increased prostate gland tumor incidence ( J:222916 )

♂ • 4 of 11 mice administered doxycycline at 3 months of age develop prostate tumors with age

♂ • tumors include adenocarcinomas, sarcomatoid carcinomas (epithelial-mesenchymal transition-like epithelial tumor), and stromal-type tumors

increased prostate gland adenocarcinoma incidence ( J:222916 )

♂

reproductive system

increased prostate gland tumor incidence ( J:222916 )

♂ • 4 of 11 mice administered doxycycline at 3 months of age develop prostate tumors with age

♂ • tumors include adenocarcinomas, sarcomatoid carcinomas (epithelial-mesenchymal transition-like epithelial tumor), and stromal-type tumors

increased prostate gland adenocarcinoma incidence ( J:222916 )

♂

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
prostate cancer		DOID:10283	OMIM:176807 OMIM:300147 OMIM:300704 OMIM:601518 OMIM:602759 OMIM:608656 OMIM:608658 OMIM:609299 OMIM:609558 OMIM:610321 OMIM:610997 OMIM:611100 OMIM:611868 OMIM:611928 OMIM:611955 OMIM:611958 OMIM:611959	J:222916

Genotype
MGI:5316652

cx3

• Allelic Composition: Col1a1^{tm1(tetO-YAP1*)Fcam}/Col1a1⁺; Tg(Cebpb-tTA)#Bjd/0
• Genetic Background: involves: 129S4/SvJae * C57BL/6

liver/biliary system

decreased hepatocyte apoptosis ( J:141457 )

• resistance to Fas-mediated apoptosis after doxycycline withdrawal

increased hepatocyte proliferation ( J:141457 )

• after doxycycline withdrawal

enlarged liver ( J:141457 )

• 4-fold after doxycycline withdrawal for 35 days

• however, increased liver size is reversible by treatment with doxycycline

increased liver weight ( J:141457 )

• after doxycycline withdrawal

• however, increased liver weight is reversible by treatment with doxycycline

liver hyperplasia ( J:141457 )

• after doxycycline withdrawal

abnormal hepatocyte morphology ( J:141457 )

• dysplastic hepatocytes with irregular, enlarged nuclei and a high to nuclear to cytoplasmic ratio after doxycycline withdrawal

cellular

decreased hepatocyte apoptosis ( J:141457 )

• resistance to Fas-mediated apoptosis after doxycycline withdrawal

increased hepatocyte proliferation ( J:141457 )

• after doxycycline withdrawal

growth/size/body

enlarged liver ( J:141457 )

• 4-fold after doxycycline withdrawal for 35 days

• however, increased liver size is reversible by treatment with doxycycline

increased liver weight ( J:141457 )

• after doxycycline withdrawal

• however, increased liver weight is reversible by treatment with doxycycline

liver hyperplasia ( J:141457 )

• after doxycycline withdrawal

Genotype
MGI:5316663

cx4

• Allelic Composition: Col1a1^{tm1(tetO-YAP1*)Fcam}/Col1a1⁺; Gt(ROSA)26Sor^{tm1(rtTA*M2)Jae}/Gt(ROSA)26Sor⁺
• Genetic Background: involves: 129S4/SvJae * C57BL/6

mortality/aging

premature death ( J:141457 )

• mice become ill and must be euthanized 4-6 days after doxycycline treatment

digestive/alimentary system

abnormal intestinal goblet cell morphology ( J:141457 )

• mature goblet cells are absent 5 days after doxycycline treatment

• however, the absence of mature goblet cells is reversed by doxycycline-withdrawal and administration of dipenzazepine increased goblet cell numbers

abnormal enterocyte proliferation ( J:141457 )

• increased proliferation of epithelium cells in the crypt regions, villus regions and at the tip of the villi of undifferentiated progenitor cells in doxycycline-treated mice

• dipenzazepine administration decreases cell proliferation in the intestine of mice treated with doxycycline

• however, proliferation of undifferentiated cells is reversed by doxycycline-withdrawal

increased pancreatic acinar cell number ( J:141457 )

• in doxycycline-treated mice

abnormal intestinal epithelium morphology ( J:141457 )

• severe dysplasia in doxycycline-treated mice

absent Paneth cells ( J:141457 )

• Paneth cells are absent 5 days after doxycycline treatment

• however, the absence of Paneth cells is reversed by doxycycline-withdrawal

endocrine/exocrine glands

increased pancreatic acinar cell number ( J:141457 )

• in doxycycline-treated mice

absent Paneth cells ( J:141457 )

• Paneth cells are absent 5 days after doxycycline treatment

• however, the absence of Paneth cells is reversed by doxycycline-withdrawal

enlarged pancreas ( J:141457 )

• in doxycycline-treated mice

pancreatic acinar-to-ductal metaplasia ( J:141457 )

• ductal metaplasia of pancreatic acinar cells in doxycycline-treated mice

cellular

abnormal intestinal goblet cell morphology ( J:141457 )

• mature goblet cells are absent 5 days after doxycycline treatment

• however, the absence of mature goblet cells is reversed by doxycycline-withdrawal and administration of dipenzazepine increased goblet cell numbers

abnormal enterocyte proliferation ( J:141457 )

• increased proliferation of epithelium cells in the crypt regions, villus regions and at the tip of the villi of undifferentiated progenitor cells in doxycycline-treated mice

• dipenzazepine administration decreases cell proliferation in the intestine of mice treated with doxycycline

• however, proliferation of undifferentiated cells is reversed by doxycycline-withdrawal

increased cell proliferation ( J:141457 )

• in the epidermis of doxycycline-treated mice

homeostasis/metabolism

decreased alkaline phosphatase activity ( J:141457 )

• absent in the small intestine 5 days after doxycycline treatment

integument

thick skin ( J:141457 )

• in doxycycline-treated mice

growth/size/body

enlarged pancreas ( J:141457 )

• in doxycycline-treated mice